Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.
Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.